analyst atul rastogi 91 22 2679 6960 indiainfoline com abhimanyu verma 2685 0101 it s all about money honey dealing sandeepa vij 98201 92387 biren patel 98204 43920 august 2003 indian pharmaceutical sector big pharma opportunity research 28 recommendations buy sun cmp rs495 ranbaxy rs952 dr reddy lab rs1094 matrix rs755 divi rs647 cipla rs920 investment case is poised for high consistent growth over the next few years driven by a multitude of factors with proven skills in chemical synthesis process development and manufacturing companies both large medium sized will benefit from booming generics market us western europe longer term opportunities outsourced custom bulk actives intermediates trials etc offer scope to grow thus we have heady potion growing near long recognized competitive relative valuations may seem expensive but believe are justified given expected earnings 18 20 two lower risk that our top picks short
